CORE COORDINATING CENTER
Prof. Harald Hampel is the P.I. and Coordinator of the Sorbonne University – “Clinical Research Group in Alzheimer Precision Medicine” (GRC n° 21) (Sorbonne University – “Groupe de Recherche Clinique – Alzheimer Precision Medicine”, GRC-APM).
The major objective of the APM Clinical Research Group is to transform Neurology, Psychiatry, and Neuroscience embracing the Precision Medicine paradigm based on complex systems theory using systems biology and systems neurophysiology, “big data” science, and biomarker-guided integrative disease modeling (IDM) for improved detection, classification, and therapy development in Alzheimer’s Disease and other neurodegenerative diseases.
The main aims of the APM Clinical Research Group are discovering and developing:
multimodal biomarkers for risk assessment, screening, progression, diagnosis, prognosis, and staging of Alzheimer’s Disease across all disease stages by:
1) biochemical (blood [plasma/serum] & cerebrospinal fluid [CSF]) biomarkers
2) genetic - epigenetic profiling: international large-scale research networks can enable the detection and stratification of population cohorts according to genetic risk & protection variants
3) neurophysiological (EEG, MEG), and
4) structural / functional / metabolic neuroimaging (MRI, DTI, fMRI, PET) methods
These biomarkers will also present tools for enriching clinical trial designs
The APMI approach is based on the robust translational evidence that Alzheimer’s Disease is a heterogeneous entity characterized by different multiple genetic and biological subsets. In this regard, the implementation of Precision Medicine in Alzheimer’s Disease and other neurodegenerative disorders along the spectrum of the so-called brain proteinopathies with neurodegeneration will result with optimized clinical profiles based on biological and genetic features. This approach will produce better responder rates, particularly in early disease-stage clinical trials, thus providing in the next future substantial benefits to patients suffering from this disease.
The identification of multi-dimensional biological markers will allow the development of targeted translational applications supporting clinicians in providing more efficacious and helpful pharmacological treatments defined as customized (or “tailored”) – that is to say adapted – to the definite profiles of their Alzheimer’s Disease patients.
Following the Precision Medicine approach, the APM Clinical Research Group will focus on Alzheimer’s Disease as a core model of disease where the need to accurately chart all the stages of disease continuum – from preclinical to prodromal to dementia stages – is expected to be crucial for both clinical practice and drug research & development.